Cancer medicine · 2025
Incidence, Outcomes and Risk Factors for Atrial Fibrillation in Patients With JAK2V617F-Positive Myeloproliferative Neoplasms.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Teng Guangshuai, Shang Ke, Zhang Yuhui, Duan Yifan, Du Chenxiao, Wang Yan, Li Yanqi, Zhang Huiqin, Peng Lan, Wei Xiaojing, Tse Gary, Zhou Yuan, Lip Gregory Y H, Liu Tong, Yang Wei, Duan Minghui, Bai Jie
Аннотация
BACKGROUND: The incidence, outcomes and risk factors for AF in the JAK2V617F-positive MPN patients are still unknown.
METHODS: The clinical profiles of patients with JAK2V617F-positive MPN were retrospectively analyzed. Multivariable Cox regression analysis was performed to identify risk factors of AF, thereby developing a risk prediction model.
RESULTS: A total of 439 patients were included (age 57 [12-87] years; 51.3% male). AF was associated with higher risks of stroke (p = 0.036, HR = 1.987, 95% CI 1.047-3.772) and mortality (p < 0.001, HR = 3.857, 95% CI 1.836-8.103). Multivariable Cox regression showed that TET2 mutation (p = 0.042, HR = 4.361, 95% CI 1.053-18.056) and increased IL-1β (p = 0.012, HR = 5.476, 95% CI 1.547-28.123) were significant risk factors for AF in patients with JAK2V617F-positive MPN. Nomograms were constructed, allowing patients to be categorized into high- and low-risk groups. The 10-year AF-free survival rate was significantly lower in the high-risk group (62% vs. 91.7%; log-rank test: p = 0.002). The validation cohort confirmed that the survival without AF in the high-risk group was significantly worse than that in the low-risk group. The use of either interferon-α or ruxolitinib, was associated with longer AF-free survival in the high-risk group (p < 0.05).
CONCLUSION: AF was significantly associated with higher risks of stroke and mortality. TET2 mutation and increased IL-1β were independent risk factors of AF in patients with JAK2V617F-positive MPN.
METHODS: The clinical profiles of patients with JAK2V617F-positive MPN were retrospectively analyzed. Multivariable Cox regression analysis was performed to identify risk factors of AF, thereby developing a risk prediction model.
RESULTS: A total of 439 patients were included (age 57 [12-87] years; 51.3% male). AF was associated with higher risks of stroke (p = 0.036, HR = 1.987, 95% CI 1.047-3.772) and mortality (p < 0.001, HR = 3.857, 95% CI 1.836-8.103). Multivariable Cox regression showed that TET2 mutation (p = 0.042, HR = 4.361, 95% CI 1.053-18.056) and increased IL-1β (p = 0.012, HR = 5.476, 95% CI 1.547-28.123) were significant risk factors for AF in patients with JAK2V617F-positive MPN. Nomograms were constructed, allowing patients to be categorized into high- and low-risk groups. The 10-year AF-free survival rate was significantly lower in the high-risk group (62% vs. 91.7%; log-rank test: p = 0.002). The validation cohort confirmed that the survival without AF in the high-risk group was significantly worse than that in the low-risk group. The use of either interferon-α or ruxolitinib, was associated with longer AF-free survival in the high-risk group (p < 0.05).
CONCLUSION: AF was significantly associated with higher risks of stroke and mortality. TET2 mutation and increased IL-1β were independent risk factors of AF in patients with JAK2V617F-positive MPN.